Search Results

Foreign currency Share based Contributed Equity translation reserve payment reserve Retained earnings Total Consolidated Entity US$m US$m US$m US$m US$m 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 As at the beginning of the year (4,603.0) (4,634.5) (5.7) 29.1 247.7 195.1 9,612.3 8,490.2 5,251.3 4,079.9 Profit for the period - - - - - - 2,102.5 1,918.7 2,102.5 1,918.7 Other comprehensive income - - 13.3 (34.8) - - (13.6) (67.1) (0.3) (101.9) Total comprehensive income for the full year 2,102.2 1,816.8 Transactions with owners in their capacity as owners Opening balance sheet adjustment adopting AASB 16 and 15 (See Accounting Policies disclosure) - - - - - - (65.0) 74.0 (65.0) 74.0 Share based payments - - - - 81.0 52.6 - - 81.0 52.6 Dividends - - - - - - (883.1) (806.8) (883.1) (806.8) Share issues - Employee share scheme 42.0 31.5 - - - - - 42.0 31.5 Other - - - - - - (0.8) 3.3 (0.8) 3.3 As at the end of the year (4,561.0) (4,603.0) 7.6 (5.7) 328.7 247.7 10,752.3 9,612.3 6,527.6 5,251.3

US$1.85 total full year dividend per share.

The approval of Vafseo for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months is based on efficacy and safety data from the INNO 2 VATE program and an assessment of post marketing safety data from Japan where Vafseo was launched in August 2020.

NEDs Dr Brian McNamee AO Chair and Independent Non-Executive Director Full year Dr Megan Clark AC Independent Non-Executive Director Full year Professor Andrew Cuthbertson AO Independent Non-Executive Director Full year Dr Brian Daniels Independent Non-Executive Director Part year - from 1 December 2024 Ms Carolyn Hewson AO Independent Non-Executive Director Full year Ms Samantha Lewis Independent Non-Executive Director Full year Ms Marie McDonald Independent Non-Executive Director Full year Ms Elaine Sorg Independent Non-Executive Director Part year - from 1 September 2024 Ms Alison Watkins AM Independent Non-Executive Director Full year

2020

Before receiving any of this vaccine, please see the full US Prescribing Information for FLUAD.

2000 2015 2017 2020 2022 Swiss company, Novartis' influenza CSL entered the Vitaeris was In August 2022, In December ZLB, was acquired vaccine business cell and gene acquired in CSL completed 2022, CSL in 2000, and was acquired therapy field June 2020, the acquisition finalised a global Aventis Behring in 2015.

KING OF PRUSSIA, Pa. 29 Oct 2020

Income Tax Paid Income tax paid is calculated as the cash tax paid in the year 1 July 2020 - 30 June 2021.

The full year fixed reward for P Perreault was US$1,856,133, the full year cash STI payment was US$2,262,385 and the full year share based payment expense was US$3,654,625.